Related Experiment Videos
Influence of low dose enteric-coated aspirin on platelet function
1Department of Laboratory Medicine and Pathology, University of Minnesota Medical School, Minneapolis 55455.
Indian Heart Journal
|November 1, 1992
Summary
Low dose, enteric-coated aspirin effectively inhibits platelet aggregation and dense body secretion. This aspirin treatment also dose-dependently reduces platelet cyclooxygenase activity, suggesting its clinical utility.
Area of Science:
- Biochemistry
- Pharmacology
- Hematology
Background:
- The effects of low-dose, enteric-coated aspirin on human platelet function remain largely uncharacterized.
- Platelet hyperactivity and increased thromboxane formation are implicated in vascular hypertension.
Purpose of the Study:
- To evaluate the acute effects of a single daily dose of enteric-coated aspirin on platelet biochemistry, physiology, and function.
- To assess aspirin's impact on platelet aggregation, dense body secretion, and thromboxane production.
Main Methods:
- Blood samples were collected from drug-free volunteers before and after aspirin ingestion (50 mg daily).
- Platelet aggregation responses to weak agonists (epinephrine, ADP) were measured.
- Platelet cyclooxygenase activity was assessed by monitoring the conversion of radiolabeled arachidonic acid to thromboxane.
Main Results:
- A single daily dose of 50 mg enteric-coated aspirin effectively inhibited secondary wave aggregation and dense body secretion.
- Aspirin ingestion demonstrated a dose-dependent inhibition of platelet cyclooxygenase activity.
- The timing of aspirin intake (before breakfast or after lunch) did not alter its inhibitory effects.
Conclusions:
- Low-dose, enteric-coated aspirin significantly restrains platelet activity.
- This aspirin regimen may be beneficial in clinical settings where elevated thromboxane formation contributes to vascular hypertension and platelet hyperactivity.